Evidence map›Paper›PMID 37615828›Full record

ArticleThe protein journal2023

Computer-Aided Multi-Epitope Based Vaccine Design Against Monkeypox Virus Surface Protein A30L: An Immunoinformatics Approach.

S V Ramprasadh, Santhosh Rajakumar, S Srinivasan, D Susha, Sameer Sharma, Rajan Chourasiya

Abstract read
PubMed Publisher
In one paragraph

Article in The protein journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S V RamprasadhDepartment of Bioinformatics, BioNome, Bangalore, 560043, India.
Santhosh RajakumarDepartment of Bioinformatics, BioNome, Bangalore, 560043, India.
S SrinivasanDepartment of Bioinformatics, BioNome, Bangalore, 560043, India.
D SushaDepartment of Bioinformatics, BioNome, Bangalore, 560043, India.ORCID http://orcid.org/0000-0001-6593-3803
Sameer SharmaDepartment of Bioinformatics, BioNome, Bangalore, 560043, India. sameer@bionome.in.ORCID http://orcid.org/0000-0002-3456-0263
Rajan ChourasiyaDepartment of Bioinformatics, BioNome, Bangalore, 560043, India.
Institute of Bioinformatics · IN

Funding

SRNOME PRIVATE LIMITED BNM/DD/124/2022
6 · The paper itself

Abstract

Monkeypox, a viral zoonotic disease resembling smallpox, has emerged as a significant national epidemic primarily in Africa. Nevertheless, the recent global dissemination of this pathogen has engendered apprehension regarding its capacity to metamorphose into a sweeping pandemic. To effectively combat this menace, a multi-epitope vaccine has been meticulously engineered with the specific aim of targeting the cell envelope protein of Monkeypox virus (MPXV), thereby stimulating a potent immunological response while mitigating untoward effects. This new vaccine uses T-cell and B-cell epitopes from a highly antigenic, non-allergenic, non-toxic, conserved, and non-homologous A30L protein to provide protection against the virus. In order to ascertain the vaccine design with the utmost efficacy, protein-protein docking methodologies were employed to anticipate the intricate interactions with Toll-like receptors (TLR) 2, 3, 4, 6, and 8. This meticulous approach led the researchers to discern an optimal vaccine architecture, bolstered by affirmative prognostications derived from both molecular dynamics (MD) simulations and immune simulations. The current research findings indicate that the peptides ATHAAFEYSK, FFIVVATAAV, and MNSLSIFFV exhibited antigenic properties and were determined to be non-allergenic and non-toxic. Through the utilization of codon optimization and in-silico cloning techniques, our investigation revealed that the prospective vaccine exhibited a remarkable expression level within Escherichia coli. Moreover, upon conducting immune simulations, we observed the induction of a robust immune response characterized by elevated levels of both B-cell and T-cell mediated immunity. Moreover, as the initial prediction with in-silico techniques has yielded promising results these epitope-based vaccines can be recommended to in vitro and in silico studies to validate their immunogenic properties.

Indexed as

Epitopes, B-LymphocyteEpitopes, T-LymphocyteMonkeypox virusMpox, MonkeypoxViral VaccinesComputer-Aided DesignHumansImmunoinformaticsMolecular Docking SimulationMolecular Dynamics SimulationEpitopes, B-LymphocyteEpitopes, T-LymphocyteViral VaccinesA30LImmunonformaticsIn silicoMHCMPXVPeptide synthesisVaccines

Identifiers

PMID37615828
OpenAlexW4386116547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.